Results 201 to 210 of about 69,057 (285)

Oral paltusotine, a nonpeptide selective somatostatin receptor 2 agonist: Mass balance, absolute bioavailability and metabolism in healthy participants. [PDF]

Br J Clin Pharmacol
Luo R, Madan A, Ferrara-Cook CT, Dalvie D, Goulet L, Struthers RS, Krasner AS.   +6 more
europepmc   +1 more source

High molecular thyrotrophin ("big"-TSH) from human pituitaries : Preparation and partial characterization [PDF]

, 1977
Erhardt, F., Scriba, Peter Christian
core   +1 more source

Vasoactive neuropeptide dysregulation: A novel mechanism of microvascular dysfunction in vascular cognitive impairment

Alzheimer's &Dementia, Volume 21, Issue 11, November 2025.
Abstract INTRODUCTION Neuropeptide dysregulation and microvascular injury are involved in pathogenesis of vascular cognitive impairment (VCI); however, the underlying etiology of this pathological axis remains unclear. METHODS We investigated pathological mediators across varying severities of VCI in a rat model of chronic cerebral hypoperfusion (CCH).
Willians Tambo, Keren Powell, Steven Wadolowski, Prashin Unadkat, Eric H. Chang, Christopher LeDoux, Daniel Sciubba, Ping Wang, Patricio Huerta, Chunyan Li   +9 more
wiley   +1 more source

Blocking dopamine receptor 2 decreases gastrin levels in H. pylori-infected mice through increasing gastric somatostatin content

Q. Shen, Yueyue Zhou, Yanlin Wang, Qi Yao, Dongbo Lian, Zhe-Hong Li, Mengfei Chen, Xiaoli Zhang, Yue Zhang, Song Jin, Li‐Fei Zheng, Jin‐Xia Zhu   +11 more
openalex   +1 more source

Inhibition of growth and metastatic progression of pancreatic carcinoma in hamster after somatostatin receptor subtype 2 (sst2) gene expression and administration of cytotoxic somatostatin analog AN-238

, 2000
Naoual Benali, Pierre Cordelier, Denis Calise, Philippe Pagès, Philippe Rochaix, Attila Nagy, Jean‐Pierre Estève, Parviz M. Pour, Andrew V. Schally, Nicole Vaysse, Christiane Susini, Louis Buscail   +11 more
openalex   +2 more sources

Supplementary Material for: Detection of abdominal lymph node metastasis from pancreatic neuroendocrine tumor by somatostatin receptor scintigraphy: Comparison with somatostatin receptors type 2 immunostaining

, 2023
Kazuhiro Kitajima, Hideyuki Shiomi, Takako Kihara, Seiko Hirono, Ryosuke Nakano, Takenori J. Okamoto, Chie Yagi, E. J. H., Kana Matsuda, Masahiko Hatano, Mamoru Yoshida, Hiroshi Kono, Seiichi Hirota, Toshiyuki Minami, Koichiro Yamakado   +14 more
openalex   +1 more source

Taking Down the Primary Cilium: Pathways for Disassembly in Differentiating Cells

BioEssays, Volume 47, Issue 11, November 2025.
Primary cilia are developmentally essential subcellular signaling compartments. However, many differentiated cells lack primary cilia, and cilia disassembly in these tissue contexts has been largely overlooked. We highlight several pathways for primary cilia loss and examine how changes in ciliation states could contribute to diverse pathologies ...
Carolyn M. Ott, Saikat Mukhopadhyay
wiley   +1 more source

Advances in radiopharmaceuticals for cancer radiotheranostics: CCK2R targeting as a paradigm for translational innovation

Cancer Communications, Volume 45, Issue 11, Page 1431-1455, November 2025.
Abstract Radiopharmaceuticals are reshaping the landscape of cancer therapy, offering a unique theranostic advantage that is becoming increasingly central to precision medicine. By labeling the same molecular scaffold with different radionuclides, these agents enable seamless integration of diagnostic imaging and targeted therapy.
Jing Li, Xuejun Wen, Rebeka Rita Reszegi, Hemavarshini Kamalrhaj, Wolfgang J. Parak, Xiaoyuan Chen, Jingjing Zhang   +6 more
wiley   +1 more source

Supplementary Figure 1 from ¹⁷⁷Lu-DOTA-EB-TATE, a Radiolabeled Analogue of Somatostatin Receptor Type 2, for the Imaging and Treatment of Thyroid Cancer

, 2023
Shilpa Thakur, Brianna Daley, Corina Millo, Craig Cochran, Orit Jacobson, Huiyan Lu, Zhantong Wang, Dale O. Kiesewetter, Xiaohong Chen, Vasyl Vasko, Joanna Kłubo-Gwieździńska   +10 more
openalex   +1 more source

Attribute Preferences for Somatostatin Analogues in Neuroendocrine Tumours (NETs) Among Patients, Clinicians and Nurses in Australia

Cancer Medicine, Volume 14, Issue 21, November 2025.
ABSTRACT Background Long‐acting somatostatin analogues (LA SSAs) are commonly used as first‐line treatment in well‐differentiated low and intermediate grade 1–2 gastroenteropancreatic neuroendocrine tumours (GEP‐NETs). As a long‐term treatment option for NETs, treatment preferences should be taken into consideration.
Simon J. Fifer, Karen Winkler, Meredith Cummins, Hima Cherian   +3 more
wiley   +1 more source